BTIG Initiates Coverage On Neuronetics with Buy Rating, Announces Price Target of $5

Benzinga Newsdesk www.benzinga.com Neutral 60.3%

Neg 0% Neu 60.3% Pos 0%

BTIG analyst Sam Eiber initiates coverage on Neuronetics (NASDAQ:STIM) with a Buy rating and announces Price Target of $5.